Cargando…
Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
BACKGROUND/AIMS: Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and microbiota composition in I...
Autores principales: | Jalanka, Jonna, Lam, Ching, Bennett, Andrew, Hartikainen, Anna, Crispie, Fiona, Finnegan, Laura A, Cotter, Paul D, Spiller, Robin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Neurogastroenterology and Motility
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026366/ https://www.ncbi.nlm.nih.gov/pubmed/33795545 http://dx.doi.org/10.5056/jnm20205 |
Ejemplares similares
-
Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018) -
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
por: Leighton, Matthew P, et al.
Publicado: (2013) -
Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery
por: Jalanka, Jonna, et al.
Publicado: (2023) -
Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012) -
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)